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 Pharmacovigilance using Clinical Text 
Paea LePendu, Srinivasan V Iyer, Anna Bauer-Mehren, Rave Harpaz,  
Yohannes T Ghebremariam, John P Cooke, Nigam H Shah 
Stanford University, Stanford, CA
Abstract. The current state of the art in post-marketing drug surveillance utilizes voluntarily submitted reports of 
suspected adverse drug reactions. We present data mining methods that transform unstructured patient notes taken 
by doctors, nurses and other clinicians into a de-identified, temporally ordered, patient-feature matrix using 
standardized medical terminologies. We demonstrate how to use the resulting high-throughput data to monitor for 
adverse drug events based on the clinical notes in the EHR. 
 
Introduction. We show that it is possible to investigate adverse drug event associations with high accuracy (46% 
sensitivity, 91% specificity) by analyzing textual notes in a clinical data warehouse using automated methods. We 
examine suspected associations for confounding via stratification and propensity score matching. We find that such 
an analysis of textual clinical notes could detect adverse drug events 2 years before the official alert. Using this 
approach we find that proton pump inhibitors (PPIs) as a class appear strongly associated with major adverse 
cardiovascular events, increasing the risk of myocardial infarction by 20-50% depending upon the individual PPI. 
The association of PPIs with such events was hypothesized based on experimental results that show that PPIs, as a 
class, elevate plasma levels of asymmetric dimethylarginine, a disease marker and an independent predictor of major 
adverse cardiovascular events. 
Methods. We use an ontology-based text processing workflow 
to tag a corpus of 9,078,736 time-stamped textual notes from 
the Stanford University Medical Center with drug and disease 
concepts and create a concept timeline for each patient. These 
timelines form a patient–feature matrix. We construct 2x2 
contingency tables utilizing temporal information in the matrix, 
e.g., to account for prior history. We calculate odds ratios, and 
apply propensity score adjustment on age, gender, race, length 
of observation, and co-morbidity and co-prescription counts. 
Results. We can reproduce the rofecoxib (Vioxx) signal and 
other well-known drug recalls or alerts, finding two-thirds of 
them before the official alert. Our method performs well, with 
an area under the receiver operator characteristic curve of 79% 
on a reference standard, with a sensitivity of 46% at a 
specificity of 91%. Given pre-clinical evidence suggesting 
mechanistic effects that may cause PPIs to independently 
elevate the risk of MI in the general population, we also see 
evidence of that risk (independent of clopidogrel, a 
controversial explanation). The figure shows a few of the well-
known positive cases as well as odds ratios for each of the 
common PPIs. The strata consisting of patients not taking 
clopidrogrel suggest that its attenuation is moot. 
Conclusion. We conclude that analyzing clinical notes presents 
a new approach for investigating questions about drug safety 
using observational data. Research on the risks of PPIs is ongoing, including studies in humans. 
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Figures and Figure Legends 
 
 
Figure 1 Odds for myocardial infarction (MI) given proton pump inhibitor use: The x-axis is the OR. The 
plots also show the number of patients exposed (exp) and affected (aff) by each drug when testing for the 
strength of association with MI. Risks given PPIs are calculated using unadjusted methods (grey), adjusting for 
exposure propensity (PSM, blue), as well as by stratification on patients not taking clopidogrel (red). The size of 
the dot is proportional to the number of exposed patients and the lines on either side show the 95% confidence 
interval. We can see that adjusting using propensity score matching results in a slight reduction in risk 
estimates, but the overall risk trend remains. The risk estimate is higher in patients not taking clopidogrel. 
Details of each plot as well as comparative risks between each drug in each class, e.g., pantoprazole versus 
rabeprazole, can be found in Supplementary Material: PPI tables. 
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